Biomerica, Inc. (Nasdaq: BMRA) is a biomedical technology company founded in 1971 by Joseph H. Irani, headquartered in Irvine, California. The company develops, manufactures, and markets diagnostic and therapeutic products used to detect and monitor a range of medical conditions, with test kits that analyze blood, urine, nasal, and fecal samples in clinics, hospitals, laboratories, physicians' offices, and at-home settings.
Biomerica's core focus is on gastrointestinal and inflammatory diseases, food intolerances, and diabetes, alongside a range of specialized esoteric tests. One of its key initiatives is InFoods IBS, a diagnostic-guided therapy that uses a blood sample to identify specific foods that may worsen a patient's irritable bowel syndrome symptoms, reflecting the company's shift toward combining diagnostics with more targeted, personalized treatment approaches. The company also gained attention during the COVID-19 pandemic for developing a rapid antigen test to help monitor and manage the disease.
The company operates as a single reportable segment, but its revenue is geographically diversified, with a significant share generated in Asia alongside sales in Europe, North America, the Middle East, and South America. This international distribution network is an important factor in any analysis of Biomerica, since currency movements, regional regulatory approvals, and demand shifts in specific markets can meaningfully affect results for a company of its size.
As a small-cap diagnostics company, Biomerica's outlook is closely tied to the pace at which its pipeline products, including InFoods IBS, move through regulatory approval and into commercial adoption, alongside its ability to grow higher-margin product lines and contract manufacturing services.
On this page you can track Biomerica's stock price, financial metrics, earnings reports, and technical analysis, alongside a comparison with other diagnostics and medical device companies.